[go: up one dir, main page]

CL2022003004A1 - Agentes de unión a ilt y métodos para su uso - Google Patents

Agentes de unión a ilt y métodos para su uso

Info

Publication number
CL2022003004A1
CL2022003004A1 CL2022003004A CL2022003004A CL2022003004A1 CL 2022003004 A1 CL2022003004 A1 CL 2022003004A1 CL 2022003004 A CL2022003004 A CL 2022003004A CL 2022003004 A CL2022003004 A CL 2022003004A CL 2022003004 A1 CL2022003004 A1 CL 2022003004A1
Authority
CL
Chile
Prior art keywords
binding agents
methods
ilt
ilt2
ilt4
Prior art date
Application number
CL2022003004A
Other languages
English (en)
Inventor
Yan Wang
Dana Yen Mei Duey
Jr Allen James Ebens
Daniel David Kaplan
Chia-Ying Kao Lam
Kalyani Mondal
Geoffrey William Stone
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of CL2022003004A1 publication Critical patent/CL2022003004A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona agentes de unión, tales como anticuerpos, que se unen específicamente a ILT2, ILT4 o ILT2 e ILT4, así como composiciones que comprenden los agentes de unión, y métodos para su uso. La descripción también proporciona polinucleótidos y vectores relacionados que codifican los agentes de unión y las células que comprenden los agentes de unión.
CL2022003004A 2020-05-01 2022-10-27 Agentes de unión a ilt y métodos para su uso CL2022003004A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019068P 2020-05-01 2020-05-01
US202063122848P 2020-12-08 2020-12-08

Publications (1)

Publication Number Publication Date
CL2022003004A1 true CL2022003004A1 (es) 2023-06-23

Family

ID=76012027

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003004A CL2022003004A1 (es) 2020-05-01 2022-10-27 Agentes de unión a ilt y métodos para su uso

Country Status (15)

Country Link
US (2) US11802155B2 (es)
EP (1) EP4143229A1 (es)
JP (1) JP2023523628A (es)
KR (1) KR20230005978A (es)
CN (2) CN116589581A (es)
AU (1) AU2021265801A1 (es)
BR (1) BR112022021684A2 (es)
CA (1) CA3181197A1 (es)
CL (1) CL2022003004A1 (es)
CO (1) CO2022015208A2 (es)
IL (1) IL297748A (es)
MX (1) MX2022013466A (es)
PE (1) PE20221894A1 (es)
TW (1) TW202206463A (es)
WO (1) WO2021222544A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210122819A1 (en) * 2018-01-18 2021-04-29 Adanate, Inc. Anti-lilrb antibodies and uses thereof
US12071479B2 (en) 2020-08-12 2024-08-27 Biond Biologics Ltd. Antibodies against ILT2 and use thereof
WO2023077521A1 (en) * 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
IL315487A (en) * 2022-03-07 2024-11-01 Agenus Inc ANTI-ILT2 antibodies and their uses
WO2023170434A1 (en) 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
WO2023235706A1 (en) * 2022-05-31 2023-12-07 Ngm Biopharmaceuticals, Inc. Combination therapies using ilt-binding agents and pd-1 inhibitors
WO2024120526A1 (zh) * 2022-12-09 2024-06-13 诺纳生物（苏州）有限公司 抗ilt4抗体及其制备方法和应用
WO2024133940A2 (en) * 2022-12-23 2024-06-27 Iomx Therapeutics Ag Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
EP4491230A1 (en) * 2023-07-14 2025-01-15 iOmx Therapeutics AG Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof
WO2024218650A1 (en) * 2023-04-19 2024-10-24 Pfizer Inc. Lilrb1 and lilrb2 antibodies and methods of use thereof
GB202314087D0 (en) * 2023-09-14 2023-11-01 Macomics Ltd Biomarker for cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE456656T1 (de) 1996-12-06 2010-02-15 Schering Corp Isolierte gene aus säuger monozyten und betreffende reagentien
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US20060078564A1 (en) 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
AU2002345878A1 (en) 2001-06-25 2003-01-08 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040241167A1 (en) 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
US20050238643A1 (en) 2001-11-14 2005-10-27 Arm Jonathan P Modulation of lir function to treat rheumatoid arthritis
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
JP2009529490A (ja) 2006-01-23 2009-08-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ニューロンの可塑性および再生を増強するための組成物および方法
WO2008061019A2 (en) 2006-11-14 2008-05-22 Genentech, Inc. Modulators of neuronal regeneration
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
KR20100109923A (ko) 2007-12-11 2010-10-11 제넨테크, 인크. 뉴런 재생의 조정인자
CL2009001155A1 (es) 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
MX2010012299A (es) 2008-05-13 2010-12-06 Genentech Inc Anticuerpos anti-pirb.
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
EP2850102A1 (en) 2012-05-15 2015-03-25 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US10138286B2 (en) 2013-03-12 2018-11-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
PT2992017T (pt) 2013-05-02 2021-01-29 Anaptysbio Inc Anticorpos dirigidos contra a morte programada 1 (pd-1)
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
KR20170007449A (ko) 2014-05-22 2017-01-18 프레드 헛친슨 켄서 리서치 센터 조혈 전구체 세포의 lilrb2 및 노치 매개 증식
US20170274003A1 (en) 2014-09-16 2017-09-28 The Board Of Trustees Of The Leland Stanford Junior University Blocking pirb upregulates spines and functional synapses to unlock visual cortical plasticity and facilitate recovery from amblyopia
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016127247A1 (en) 2015-02-11 2016-08-18 University Health Network Methods and compositions for modulating lilr proteins
CA3218106A1 (en) 2015-03-06 2016-09-15 The Board Of Regents Of The University Of Texas System Anti-lilrb antibodies and their use in detecting and treating cancer
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017042816A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Ablation of perforin positive dendritic cells in cancer treatment
CA3019635A1 (en) 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
EP3344263A4 (en) 2016-08-04 2020-07-01 Memorial Sloan-Kettering Cancer Center CANCER ANTIGEN TARGETS AND USES THEREOF
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
WO2019107387A1 (ja) 2017-11-28 2019-06-06 国立大学法人大阪大学 マラリア治療薬、マラリアの治療方法、マラリア治療用候補物質のスクリーニング方法、マラリア重症化マーカー、マラリアの重症化の危険度を試験する方法および試験試薬
EP3728318A2 (en) 2017-12-22 2020-10-28 Jounce Therapeutics, Inc. Antibodies for lilrb2
US20210122819A1 (en) 2018-01-18 2021-04-29 Adanate, Inc. Anti-lilrb antibodies and uses thereof

Also Published As

Publication number Publication date
IL297748A (en) 2022-12-01
CN116589581A (zh) 2023-08-15
PE20221894A1 (es) 2022-12-13
US20240025997A1 (en) 2024-01-25
KR20230005978A (ko) 2023-01-10
CN115768524A (zh) 2023-03-07
BR112022021684A2 (pt) 2023-01-17
TW202206463A (zh) 2022-02-16
WO2021222544A1 (en) 2021-11-04
AU2021265801A1 (en) 2022-11-17
CO2022015208A2 (es) 2023-01-16
US20210355211A1 (en) 2021-11-18
MX2022013466A (es) 2022-11-16
JP2023523628A (ja) 2023-06-06
EP4143229A1 (en) 2023-03-08
CA3181197A1 (en) 2021-11-04
US11802155B2 (en) 2023-10-31

Similar Documents

Publication Publication Date Title
CL2022003004A1 (es) Agentes de unión a ilt y métodos para su uso
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
CL2022003684A1 (es) Agentes de unión a lair-1 y métodos para su uso
CL2020003031A1 (es) Agentes aglutinantes del psma y usos de estos.
CL2023000907A1 (es) Anticuerpos de unión a gprc5d
AR116718A1 (es) Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar infección vírica
DOP2019000253A (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
CO2021016907A2 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
CO6721052A2 (es) Anticuerpos para e receptor de la barrera hematoencefálica de baja afinidad y sus usos
UY37258A (es) AGENTES REVERSORES DE UNIÓN PARA ANTICUERPOS ANTI-FACTOR XI/XIa Y SUS USOS
CO2020013468A2 (es) Agentes de unión a c3 y métodos para su uso
CO2023010208A2 (es) Proteínas de unión a psma y usos de estas
CL2019002081A1 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas.
AR122674A1 (es) Anticuerpos de unión a cd3 y cd19
CO2022013823A2 (es) Materiales y métodos para la unión de siglec-3/cd33
CL2022000052A1 (es) Anticuerpos de pre–direccionamiento y metodos de uso
AR121974A1 (es) Agentes de unión a ilt y métodos para su uso
AR122678A1 (es) Agentes de unión a lair-1 y métodos para su uso